Riskpilot← Back to searchSign inGet full accessRoche Oy
OYActiveY-tunnus 0498521-4Revontulenpuisto 2-CWholesale of pharmaceutical and medical goods · NACE 4646Est. 1983— employees
Revenue 2025
EUR 81,4M
+4% vs 2024
EBITDA margin
3.0%
+2% vs 2024
Equity ratio
23.4%
Financial strength
Net profit 2025
EUR 1,9M
0% vs 2024
| Revenue | EUR 81,4M | +4% |
| EBITDA | EUR 2,4M | +2% |
| Net profit | EUR 1,9M | +0% |
| Total assets | EUR 38,6M | -4% |
| Equity | EUR 9M | -26% |
| Employees | — | — |
Legal name
Roche Oy
Y-tunnus number
0498521-4
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. helmikuuta 1983
Share capital
EUR 51 000
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsenet kaksi yhdessä
Company purpose
Föremålet för bolagets verksamhet är att bedriva närings- och informationsverksamhet inom hälsovårds- och kemiska branscherna samt annan därmed förenlig verksamhet.
Address
Revontulenpuisto 2-C
Phone
+358010554500
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 74 719 | 70 857 | 71 981 | 78 464 | 81 416 |
| Staff expenses | −11 270 | −10 806 | −10 358 | −10 069 | −10 479 |
| EBITDA | 5 753 | 3 132 | 2 942 | 2 382 | 2 422 |
| Depreciation & amort. | −149 | −147 | −147 | −146 | −146 |
| EBIT | 5 604 | 2 986 | 2 796 | 2 235 | 2 276 |
| Net financials | −25 | −9 | −11 | 239 | 147 |
| Profit before tax | 5 579 | 2 977 | 2 784 | 2 474 | 2 423 |
| Tax | 1 109 | 592 | 590 | 594 | 546 |
| Net profit | 4 470 | 2 385 | 2 194 | 1 880 | 1 877 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 30 765 | 30 336 | 29 187 | 40 029 | 38 571 |
| Equity | 10 703 | 13 089 | 10 282 | 12 162 | 9 039 |
| Long-term debt | 2 954 | 2 485 | 0 | 0 | 0 |
| Short-term debt | 17 108 | 14 762 | 18 904 | 27 566 | 29 232 |
| Total debt | 20 062 | 17 248 | 18 904 | 27 566 | 29 232 |
EBITDA margin
3.0%
This company
15.8%
Market median
-81% vs market
20212025
Equity ratio
23.4%
This company
38.2%
Market median
-39% vs market
20212025
Return on equity
20.8%
This company
18.4%
Market median
+13% vs market
20212025
Net profit margin
2.3%
This company
8.1%
Market median
-72% vs market
20212025
Asset turnover
2.11×
This company
1.12×
Market median
+88% vs market
20212025
Debt / equity
3.27×
This company
0.62×
Market median
-427% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
HM Confidential Clerk | Confidential Clerk | 2024 |
AH Confidential Clerk | Confidential Clerk | 2020 |
LS Chief Executive Officer | Chief Executive Officer | 2024 |
AP Confidential Clerk | Confidential Clerk | 2019 |
TM Confidential Clerk | Confidential Clerk | 2023 |
| Former (9) | ||
HM Confidential Clerk | Confidential Clerk | 2020 – 2023 |
PC | Audit | 2010 – 2023 |
SG Confidential Clerk | Confidential Clerk | 2020 – 2024 |
DD Chief Executive Officer | Chief Executive Officer | 2023 – 2024 |
MH Confidential Clerk | Confidential Clerk | 2017 – 2020 |
MT Chief Executive Officer | Chief Executive Officer | 2017 – 2021 |
DD Chief Executive Officer | Chief Executive Officer | 2021 – 2023 |
NJ Confidential Clerk | Confidential Clerk | 2017 – 2019 |
MP Confidential Clerk | Confidential Clerk | 2017 – 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairperson | 2025 | |
| Board of Directors | 2024 | |
| Board of Directors | 2019 | |
| Former (5) | ||
| Chairperson | 2023 – 2025 | |
| Board of Directors | 2021 – 2024 | |
| Board of Directors | 2018 – 2020 | |
| Board of Directors | 2018 – 2019 | |
| Chairperson | 2018 – 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Roche Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Heidi Marita Saanila-Sotamaa | Confidential Clerk | 0 companies |
| Hongli Mao | Confidential Clerk | 0 companies |
| Petra Camilla Pörnull | Audit | 0 companies |
| Stefan Georg Lindinger | Confidential Clerk | 0 companies |
| David Daniel Thomas Traub | Chief Executive Officer | 0 companies |
| Anna Helena Manner-Raappana | Confidential Clerk | 0 companies |
| Merja Helena Mäkelä | Confidential Clerk | 0 companies |
| Maturin Tchoumi | Chief Executive Officer | 0 companies |
| David Daniel Thomas Traub | Chief Executive Officer | 0 companies |
| Lisa Slater | Chief Executive Officer | 0 companies |
| Nina Johanna Isonen-Sjölund | Confidential Clerk | 0 companies |
| Anssi Pekka Linnankivi | Confidential Clerk | 0 companies |
| Tiina Maria Korpelainen | Confidential Clerk | 0 companies |
| Matteo Pietra | Confidential Clerk | 0 companies |
| Isabel Marianne Joerin | Chairperson | 0 companies |
| Patricia Mayumi Ogochi Kamiya | Board of Directors | 0 companies |
| Isabel Marianne Boissonnas | Chairperson | 0 companies |
| Ehab Abdelmoneim Youssef Hassan | Board of Directors | 0 companies |
| Matheus Barbosa Vieira | Board of Directors | 0 companies |
| Timo Juhani Niskanen | Board of Directors | 0 companies |
| Luc Jozef Leon Dirckx | Board of Directors | 0 companies |
| Beat Christoph Krähenmann | Chairperson | 0 companies |